# Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 500mg and Rosuvastatin 10mg

> **NCT02011633** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 72 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** HCP1201 500/10mg
- **DRUG:** Metformin SR 500mg
- **DRUG:** Rosuvastatin 10mg

## Key facts

- **NCT ID:** NCT02011633
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2013-11
- **Final completion:** 2013-12
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2014-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02011633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02011633, "Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 500mg and Rosuvastatin 10mg". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02011633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*